Publicaciones en las que colabora con Vicente E. Climent Payá (49)

2019

  1. Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study

    Circulation. Heart failure, Vol. 11, Núm. 1, pp. e004124

2016

  1. Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy

    European Journal of Clinical Investigation, Vol. 46, Núm. 2, pp. 123-129

  2. Evidencia del tratamiento con marcapasos en la miocardiopatía hipertrófica obstructiva

    Revista Espanola de Cardiologia

2015

  1. Importance of sudden cardiac death risk stratification in hypertrophic cardiomyopathy

    Revista Espanola de Cardiologia

  2. Involvement of the -420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy

    Journal of Internal Medicine, Vol. 278, Núm. 1, pp. 50-58

2014

  1. Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy

    QJM, Vol. 107, Núm. 8, pp. 613-621

2013

  1. Identification and confirmation of haptoglobin as a potential serum biomarker in hypertrophic cardiomyopathy using proteomic approaches

    Annals of Medicine, Vol. 45, Núm. 4, pp. 341-347

2012

  1. Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy

    European Journal of Internal Medicine, Vol. 23, Núm. 2, pp. 169-174

2010

  1. Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with ischemic heart disease

    International Journal of Cardiology, Vol. 139, Núm. 1, pp. 95-97

  2. Enzyme replacement therapy in fabry disease: Influence on cardiac manifestations

    Current Medicinal Chemistry, Vol. 17, Núm. 16, pp. 1679-1689

  3. Plasma levels of Von Willebrand factor are increased in patients with hypertrophic cardiomyopathy

    Thrombosis Research, Vol. 126, Núm. 1

  4. Serum Levels of high-sensitivity troponin T: A novel marker for cardiac remodeling in hypertrophic cardiomyopathy

    Journal of Cardiac Failure, Vol. 16, Núm. 12, pp. 950-956

2009

  1. Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation

    International Journal of Cardiology, Vol. 132, Núm. 2, pp. 227-232

  2. Left atrial remodelling in hypertrophic cardiomyopathy: Relation with exercise capacity and biochemical markers of tissue strain and remodelling

    International Journal of Clinical Practice, Vol. 63, Núm. 10, pp. 1465-1471

  3. ¿Existe un efecto beneficioso a largo plazo con el tratamiento con marcapasos de la miocardiopatía hipertrófica obstructiva severa?

    Revista Espanola de Cardiologia, Vol. 62, Núm. 11, pp. 1233-1239

2008

  1. Cardiorresonancia magnética con gadolinio y capacidad de esfuerzo en la miocardiopatía hipertrófica

    Revista Espanola de Cardiologia, Vol. 61, Núm. 8, pp. 853-860

  2. Short- and long-term effects of growth hormone on the heart

    International Journal of Cardiology, Vol. 124, Núm. 3, pp. 393-394

  3. Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications

    Journal of Cardiac Failure, Vol. 14, Núm. 5, pp. 414-419

2007

  1. Pharmacologic therapy in growth hormone disorders and the heart

    Current Medicinal Chemistry, Vol. 14, Núm. 13, pp. 1399-1407